Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorGrande, E.
dc.contributor.authorGarcia-Carbonero, R.
dc.contributor.authorTeule, A.
dc.contributor.authorBenavent Vinuales, M.
dc.contributor.authorJimenez-Fonseca, P.
dc.contributor.authorMolina-Cerrillo, J.
dc.contributor.authorLopez, C.
dc.contributor.authorCustodio, A.
dc.contributor.authorHierro, C.
dc.contributor.authorGallego, J.
dc.contributor.authorAlonso, V.
dc.contributor.authorCarmona-Bayonas, A.
dc.contributor.authorLlanos, M.
dc.contributor.authorSevilla, I.
dc.contributor.authorHernando, J.
dc.contributor.authorLista, F.
dc.contributor.authorAnton Pascual, B.
dc.contributor.authorRuffinelli, J. C.
dc.contributor.authorGallego Jimenez, I.
dc.contributor.authorCapdevila, J.
dc.contributor.authoraffiliation[Grande, E.] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Garcia-Carbonero, R.] UCM, Hosp Univ Octubre 12, Dept Med Oncol, Imas 12, Madrid, Spain
dc.contributor.authoraffiliation[Anton Pascual, B.] UCM, Hosp Univ Octubre 12, Dept Med Oncol, Imas 12, Madrid, Spain
dc.contributor.authoraffiliation[Teule, A.] Inst Catala Oncol ICO IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Ruffinelli, J. C.] Inst Catala Oncol ICO IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Benavent Vinuales, M.] Univ Hosp Virgen del Rocio, Inst Biomed Sevilla IBIS, Dept Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Gallego Jimenez, I.] Univ Hosp Virgen del Rocio, Inst Biomed Sevilla IBIS, Dept Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Jimenez-Fonseca, P.] Hosp Univ Cent Asturias, Dept Med Oncol, ISPA, Oviedo, Spain
dc.contributor.authoraffiliation[Molina-Cerrillo, J.] Hosp Univ Ramon & Cajal, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Lopez, C.] Hosp Univ Marques de Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain
dc.contributor.authoraffiliation[Custodio, A.] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Hierro, C.] Germans Trias & Pujol Univ Hosp, Dept Med Oncol, Catalan Inst Oncol ICO Badalona, Badalona, Spain
dc.contributor.authoraffiliation[Gallego, J.] Gen Univ Elche Hosp, Dept Med Oncol, Alicante, Spain
dc.contributor.authoraffiliation[Alonso, V.] Hosp Univ Miguel Servet, Inst Aragones Invest Sanitaria, Dept Med Oncol, Zaragoza, Spain
dc.contributor.authoraffiliation[Carmona-Bayonas, A.] IMIB, Hosp Univ Morales Meseguer, Hematol & Med Oncol Dept, UMI, Murcia, Spain
dc.contributor.authoraffiliation[Llanos, M.] Hosp Univ Canarias, Dept Med Oncol, San Cristobal La Laguna, Spain
dc.contributor.authoraffiliation[Sevilla, I.] Hosp Univ Reg & Virgen Victoria Malaga, Dept Med Oncol, Inst Invest Biomed Malaga IBIMA, Invest Clin & Traslac Canc, Malaga, Spain
dc.contributor.authoraffiliation[Hernando, J.] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Capdevila, J.] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Lista, F.] MD Anderson Canc Ctr Madrid, Dept Urol, Madrid, Spain
dc.contributor.funderIpsen
dc.contributor.funderRoche
dc.date.accessioned2025-01-07T15:18:09Z
dc.date.available2025-01-07T15:18:09Z
dc.date.issued2021-09-21
dc.description.abstractAntiangiogenic agents have demonstrated antitumor properties in endocrine malignancies regardless of their primary origin. Experience with immune-checkpoint inhibitors is limited in this area and early results when used as single agents are discouraging. The aim of this trial is to assess the efficacy and safety of the combination of cabozantinib and atezolizumab, which may overcome the resistance in previously treated metastatic endocrine tumors .
dc.description.versionNo
dc.identifier.citationGrande, E., Garcia-Carbonero, R.. Teule, A., Benavent Vinuales, M., Jimenez-Fonseca, P. , Molina-Cerrillo, J., et al . Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914). Annals of Oncology. Septiembre 2021 (32), S624 - S625
dc.identifier.doi10.1016/j.annonc.2021.08.710
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.710
dc.identifier.urihttps://hdl.handle.net/10668/27029
dc.identifier.wosID700527701039
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS624-S625
dc.provenanceRealizada la curación de contenido 07/04/2025
dc.publisherElsevier
dc.relation.publisherversionhttps://www.annalsofoncology.org/article/S0923-7534(21)02939-2/fulltext
dc.rights.accessRightsRestricted Access
dc.subjectcabozantinib
dc.subjectEndocrine Gland Neoplasms
dc.subject.decsNeoplasms
dc.subject.decsEfficacy
dc.subject.decsAngiogenesis Inhibitors
dc.subject.decsSafety
dc.subject.meshatezolizumab
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshImmune Checkpoint Inhibitors
dc.titleCabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Regional Universitario de Málaga
SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía